NCT04739527View on ClinicalTrials.gov

Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Ovarian Cancer
Interventions
BIOLOGICAL

DCP-001

allogeneic dendritic cell vaccine

Trial Locations (1)

9713GZ

UMCG, Groningen

Sponsors

Collaborators (1)

Mendus
All Listed Sponsors
collaborator

Mendus

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT04739527 - Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment | Biotech Hunter | Biotech Hunter